Skip to main content

Table 4 Adjusted Hazard ratio of breast cancer survival

From: Triple-negative, basal-like, and quintuple-negative breast cancers: better prediction model for survival

  Model 1 (5-subgrouping) Model 2 (4-subgrouping)
Variables Disease-free survival Overall survival Disease-free survival Overall survival
  HR (95%CI) P-value HR (95%CI) P-value HR (95%CI) P-value HR (95%CI) P-value
Molecular subtyping         
   IHC-Luminal A      1.00   1.00  
   IHC-Luminal B      1.48 (1.04-2.09) 0.027 1.86 (1.11-3.11) 0.018
   IHC-HER2      1.60 (1.11-2.31) 0.011 3.07 (1.86-4.87) < 0.001
   IHC-TNBC      1.19 (0.89-1.68) 0.293 2.91 (1.88-4.48) < 0.001
Molecular subtyping         
   IHC-Luminal A 1.00   1.00      
   IHC-Luminal B 1.48 (1.04-2.09) 0.028 1.86 (1.11-3.11) 0.018     
   IHC-HER2 1.60 (1.11-2.31) 0.012 3.07 (1.86-4.87) < 0.001     
   IHC-BLBC 1.03 (0.68-1.56) 0.874 2.80 (1.68-4.68) < 0.001     
   IHC-QNBC/5NP 1.43 (0.93-2.18) 0.102 3.04 (1.75-5.26) < 0.001     
Tumor size (cm)         
   ≤ 2 cm 1.00   1.00   1.00   1.00  
   2-5 cm 1.39 (1.06-1.86) 0.02 2.26 (1.46-3.50) < 0.001 1.39 (1.05-1.85) 0.021 2.26 (1.46-3.39) < 0.001
   > 5cm 2.19 (1.44-3.36) < 0.001 3.21 (2.13-4.67) < 0.001 2.16 (1.42-3.32) < 0.001 3.19 (1.78-5.73) < 0.001
LN involvement         
   Negative 1.00   1.00   1.00   1.00  
   Positive 2.40 (1.82-3.16) < 0.001 3.17 (2.14-4.61) < 0.001 2.41 (1.83-3.18) < 0.001 3.17 (2.14-4.61) < 0.001
Adjuvant Chemotherapy         
   Not done 1.00   1.00   1.00   1.00  
   Done 0.70 (0.50-0.99) 0.049 0.34(0.22-0.50) < 0.001 0.70 (0.50-0.99) 0.048 0.34 (0.22-0.50) < 0.001
  1. IHC: immunohistochemistry